On Wednesday 25 November, the European Commission published its long-awaited pharmaceutical strategy, in which it commits to examining ways to improve accessibility, sustainability and security of supply in Europe (see EUROPE B12608A24). In an inception impact assessment, published alongside the strategy, the Commission puts forward a number of specific options regarding orphan and paediatric medicines.
The impact assessment is open until 6 January 2021 for comment under the ‘better...